GKOS (Glaukos) E10: $-1.74 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GKOS Glaukos Corp GKOS
78 GF Score
Price $180.02
GF Value $147.87
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Glaukos E10?

Glaukos GKOS +5.28% 78 E10 is $-1.74 as of Jun. 2026. GuruFocus rates GKOS with a GF Score™ of 78/100 and a GF Value™ of $147.87 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Glaukos's adjusted earnings per share data for the three months ended in Jun. 2026 was $-0.310. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.74 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-08-09), Glaukos's current stock price is $180.02. Glaukos's E10 for the quarter that ended in Jun. 2026 was $-1.74. Glaukos's Shiller PE Ratio of today is .


Glaukos  (NYSE:GKOS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Glaukos E10 Related Terms


Glaukos E10 Historical Data

* Premium members only.

The historical data trend for Glaukos's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glaukos E10 Chart

Glaukos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -2.44 -2.72 -1.61

Glaukos Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.36 -1.39 -1.61 -1.68 -1.74

GKOS vs BRKR, BIO, GMED: E10 Comparison

For the Medical Devices subindustry, Glaukos's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glaukos Shiller PE Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Glaukos's Shiller PE Ratio falls into.


GKOS
78GF Score
Glaukos Corp GKOS
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glaukos E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Glaukos's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.31/333.9520*333.9520
=-0.310

Current CPI (Jun. 2026) = 333.9520.

Glaukos Quarterly Data

per share eps CPI Adj_EPS
201609 0.030 241.428 0.041
201612 0.004 241.432 0.006
201703 0.020 243.801 0.027
201706 -0.100 244.955 -0.136
201709 0.040 246.819 0.054
201712 0.030 246.524 0.041
201803 -0.080 249.554 -0.107
201806 -0.150 251.989 -0.199
201809 -0.190 252.439 -0.251
201812 0.040 251.233 0.053
201903 -0.040 254.202 -0.053
201906 -0.170 256.143 -0.222
201909 -0.370 256.759 -0.481
201912 0.840 256.974 1.092
202003 -1.240 258.115 -1.604
202006 -0.900 257.797 -1.166
202009 -0.350 260.280 -0.449
202012 -0.240 260.474 -0.308
202103 -0.360 264.877 -0.454
202106 -0.380 271.696 -0.467
202109 0.130 274.310 0.158
202112 -0.470 278.802 -0.563
202203 0.110 287.504 0.128
202206 -0.960 296.311 -1.082
202209 -0.580 296.808 -0.653
202212 -0.660 296.797 -0.743
202303 -0.720 301.836 -0.797
202306 -0.680 305.109 -0.744
202309 -0.630 307.789 -0.684
202312 -0.750 306.746 -0.817
202403 -0.820 312.332 -0.877
202406 -1.000 314.175 -1.063
202409 -0.390 315.301 -0.413
202412 -0.600 315.605 -0.635
202503 -0.320 319.799 -0.334
202506 -0.340 322.561 -0.352
202509 -0.280 324.800 -0.288
202512 -2.320 324.054 -2.391
202603 -0.340 330.213 -0.344
202606 -0.310 333.952 -0.310

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-1.74 mean?
Glaukos (GKOS) has a E10 of $-1.74 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Glaukos and its competitors.
Is Glaukos' E10 too high?
Glaukos' current E10 is $-1.74. Overall, Glaukos has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' E10 compare to BRKR and BIO?
Glaukos' E10 of $-1.74 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Medical Devices & Instruments company?
A good E10 depends on the Medical Devices & Instruments industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Glaukos and its competitors. Glaukos's current E10 is $-1.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Modestly Overvalued. The stock's GF Value™ is $147.87, compared to a current price of $180.02 — trading 21.7% above its estimated fair value. The current E10 is $-1.74. Glaukos' overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Glaukos (GKOS), the current E10 is $-1.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glaukos (GKOS) Overvalued in 2026?

Based on GuruFocus' analysis, Glaukos stock appears to be overvalued. The current stock price of $180.02 is trading 21.7% above its estimated GF Value™ of $147.87. GuruFocus considers Glaukos to be Modestly Overvalued.

Key valuation signals for GKOS:

  • E10: $-1.74
  • GF Value™: $147.87 vs. price of $180.02 (21.7% above fair value)
  • GF Score™: 78/100 with 6 warning signs

No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Glaukos Business Description

Other Exchanges 6GJ:Germany
Address One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
78GF Score

Get the complete analysis for GKOS

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$180.02
Price
$147.87
GF Value